Adding metabolic agents to prostate cancer therapy: Every rose has its thorn

Eur J Cancer. 2022 Jul:170:305-307. doi: 10.1016/j.ejca.2021.04.048. Epub 2022 May 11.

Authors

Stefan A J Buck¹, Ron H J Mathijssen², Ronald de Wit³

Affiliations

¹ Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
² Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; Division Lead of Translational Pharmacology.
³ Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; Division Lead of Genitourinary Oncology. Electronic address: r.dewit@erasmusmc.nl.

PMID: 35568678
DOI: 10.1016/j.ejca.2021.04.048

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Male
Pelvis
Prostate
Prostatic Neoplasms* / drug therapy